Molecular Evolutionary Patterns in Breast Cancer

Geno-phenotypic patterns of pre-invasive and invasive lobular breast cancers and infiltrating ductal carcinomas of low, intermediate, and high grade are reviewed. One of the main differences between lobular breast cancers and ductal carcinomas is the presence of inactivating E-cadherin gene mutations in lobular breast cancers. In many other respects, lobular breast cancers and low-grade ductal carcinomas exhibit similar geno-phenotypic profiles. The development of p53 dysfunction may be a hallmark of infiltrating ductal cancers of intermediate and high grade. Sequential Her-2/neu and ras abnormalities define a subset of aggressive high-grade tumors, and the development of Rb dysfunction may define a separate subset of aggressive ductal cancers. Based on these observations, a branching molecular evolutionary model for the development and progression of breast cancer is proposed.

[1]  Albert J. Fornace,et al.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.

[2]  P. Diest,et al.  Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade , 2001, The Journal of pathology.

[3]  K. Fukasawa,et al.  p53 Mutation and Mitotic Infidelity , 2000, Cancer investigation.

[4]  S. Petruolo,et al.  Aneuploidy in breast cancer: a fluorescence in situ hybridization study. , 1995, Cytometry.

[5]  M. Greene,et al.  Genetics of breast cancer. , 1997, Mayo Clinic proceedings.

[6]  M. Stratton,et al.  Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[7]  Gustavo Droguett,et al.  DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation , 2000, Nature Cell Biology.

[8]  J Isola,et al.  Genetic alterations in lobular breast cancer by comparative genomic hybridization , 1997, International journal of cancer.

[9]  F. Schmitt,et al.  Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c‐erbB‐2 protein , 1995, Cancer.

[10]  P. V. van Diest,et al.  Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer. , 1998, Molecular pathology : MP.

[11]  W. Gullick,et al.  Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. , 1991, Cancer research.

[12]  C. Sherr The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.

[13]  R. Xu,et al.  Amplification of Her-2/neu Gene in Her-2/neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material , 2002, Modern Pathology.

[14]  J. Myles,et al.  HER2/neu amplification in breast cancer: stratification by tumor type and grade. , 2002, American journal of clinical pathology.

[15]  G. Moreno-Bueno,et al.  Correlation of Snail expression with histological grade and lymph node status in breast carcinomas , 2002, Oncogene.

[16]  T. Sofuni,et al.  Illegitimate recombination leading to allelic loss and unbalanced translocation in p53-mutated human lymphoblastoid cells , 1997, Molecular and cellular biology.

[17]  S. Hirohashi,et al.  p53 Mutations and c‐erbB‐2 Amplification in Intraductal and Invasive Breast Carcinomas of High Histologic Grade , 1993, Japanese journal of cancer research : Gann.

[18]  S. Devries,et al.  Genomic alterations in tubular breast carcinomas. , 2001, Human pathology.

[19]  Takafumi Nishizaki,et al.  Genetic alterations in primary breast cancers and their metastases: Direct comparison using modified comparative genomic hybridization , 1997, Genes, chromosomes & cancer.

[20]  J. Soares,et al.  Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. , 1999, Journal of clinical pathology.

[21]  F. Sarkar,et al.  Correlation of DNA ploidy with c-erbB-2 expression in preinvasive and invasive breast tumors. , 1991, Analytical and quantitative cytology and histology.

[22]  H Buerger,et al.  Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes , 1999, The Journal of pathology.

[23]  D. Pinkel,et al.  ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Jove,et al.  Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors , 1999, Oncogene.

[25]  W. McGuire,et al.  Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.

[26]  H. Frierson Grade and flow cytometric analysis of ploidy for infiltrating ductal carcinomas. , 1993, Human pathology.

[27]  N. Rosen,et al.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 , 2002, Oncogene.

[28]  G. Cserni Complete sectioning of axillary sentinel nodes in patients with breast cancer. Analysis of two different step sectioning and immunohistochemistry protocols in 246 patients , 2002, Journal of clinical pathology.

[29]  W. McGuire,et al.  Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. , 1992, Journal of the National Cancer Institute.

[30]  D. Spandidos,et al.  Expression of ras Rb1 and p53 proteins in human breast cancer. , 1992, Anticancer research.

[31]  M. Wigler,et al.  Signaling pathways in Ras-mediated tumorigenicity and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Shackney,et al.  Model for the genetic evolution of human solid tumors. , 1989, Cancer research.

[33]  S. Hirohashi,et al.  Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c‐erbB‐2 expression patterns in both the non‐invasive and invasive portions , 1998, Pathology international.

[34]  D. Visscher,et al.  Multiparametric deoxyribonucleic acid and cell cycle analysis of breast carcinomas by flow cytometry. Clinicopathologic correlations. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[35]  Rochelle L. Garcia,et al.  C‐ERBB‐2 oncogens protein in In situ and invasive lobular breast neoplasia , 1991 .

[36]  Sam W. Lee,et al.  Role of Pin1 in the Regulation of p53 Stability and p21 Transactivation, and Cell Cycle Checkpoints in Response to DNA Damage* , 2002, The Journal of Biological Chemistry.

[37]  D. Persons,et al.  Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[38]  P. V. van Diest,et al.  Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution , 2001, The Journal of pathology.

[39]  F. Smith,et al.  Relationships between image cytometric DNA index, proliferation fraction and multiploidy and conventional nuclear grade in breast carcinoma. , 1993, Modern Pathology.

[40]  A. Reiner,et al.  Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients , 2005, Journal of Cancer Research and Clinical Oncology.

[41]  V. Keshamouni,et al.  Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion , 2001, Oncogene.

[42]  E. Campo,et al.  CYCLIN D1 AND RETINOBLASTOMA GENE EXPRESSION IN HUMAN BREAST CARCINOMA: CORRELATION WITH TUMOUR PROLIFERATION AND OESTROGEN RECEPTOR STATUS , 1997, The Journal of pathology.

[43]  Jiri Bartek,et al.  Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.

[44]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[45]  M. J. van de Vijver,et al.  © 1997 Cancer Research Campaign , 2022 .

[46]  N. Sneige,et al.  Molecular and Biologic Markers of Premalignant Lesions of Human Breast , 2002, Advances in anatomic pathology.

[47]  I. Bièche,et al.  Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer , 2000, Molecular carcinogenesis.

[48]  W. Sauerbrei,et al.  DNA flow cytometry in node-positive breast cancer. Prognostic value and correlation with morphologic and clinical factors. , 1995, Analytical and quantitative cytology and histology.

[49]  D. Horsfall,et al.  Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Press,et al.  p53 mutations and expression in breast carcinoma in situ. , 2000, The American journal of pathology.

[51]  W. Cavenee,et al.  Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. , 1992, Human pathology.

[52]  T. Oyama,et al.  Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. , 1998, Cancer research.

[53]  P. V. van Dam,et al.  Flow cytometric detection of multifocal DNA aneuploid cell populations in mastectomy specimens containing a primary breast carcinoma. , 1990, Cytometry.

[54]  M. Osborn,et al.  Immunohistochemical profile of invasive lobular carcinoma of the breast: Predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive , 2005, Virchows Archiv A.

[55]  S. Ménard,et al.  Role of p53 in HER2-induced Proliferation or Apoptosis* , 2001, The Journal of Biological Chemistry.

[56]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[57]  S. Nordling,et al.  Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. , 1997, Acta oncologica.

[58]  S. Ingvarsson,et al.  Molecular genetics of breast cancer progression. , 1999, Seminars in cancer biology.

[59]  W. Birchmeier,et al.  Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. , 1993, The American journal of pathology.

[60]  E. Fearon,et al.  The SLUG zinc-finger protein represses E-cadherin in breast cancer. , 2002, Cancer research.

[61]  G. Berx,et al.  E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. , 1996, Oncogene.

[62]  J. Cunningham,et al.  p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. , 1995, Oncogene.

[63]  T. Julian,et al.  Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. , 2001, Cytometry.

[64]  S E Shackney,et al.  The accumulation of multiple genetic abnormalities in individual tumor cells in human breast cancers: clinical prognostic implications. , 1996, The cancer journal from Scientific American.

[65]  G. Wahl,et al.  Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[66]  G. Divine,et al.  Two-color, cytokeratin-labeled dna flow cytometric analysis of 332 breast cancers: lack of prognostic value with 12-year follow-up. , 2001, Archives of pathology & laboratory medicine.

[67]  J F Silverman,et al.  Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  S. Hirohashi,et al.  Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. , 1996, Oncogene.

[69]  K. Hirata,et al.  Detection of p53 gene mutations in fine-needle aspiration biopsied breast cancer specimens: correlations with nuclear p53 accumulations and tumor DNA aneuploidy patterns. , 1997, Cancer letters.

[70]  Persons Dl,et al.  Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .

[71]  P. Diest,et al.  Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material: Correlations between flow cytometric, clinical, and pathologic variables , 1996 .

[72]  H. Moch,et al.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.

[73]  H. Olsson,et al.  Correlation between karyotypic pattern and clinicopathologic features in 125 breast cancer cases , 1996, International journal of cancer.

[74]  L. Melton,et al.  HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  M. Oren,et al.  Regulation of p53 , 2002, Annals of the New York Academy of Sciences.

[76]  I. Nenci,et al.  Biological profile of in situ breast cancer investigated by immunohistochemical technique. , 1998, Cancer detection and prevention.

[77]  W. Gregory,et al.  The classification of ductal carcinoma in situ and its association with biological markers. , 1994, Seminars in diagnostic pathology.

[78]  N. Goldstein,et al.  Intraductal carcinoma associated with invasive carcinoma of the breast. A comparison of the two lesions with implications for intraductal carcinoma classification systems. , 1996, American journal of clinical pathology.

[79]  T. Visakorpi,et al.  Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.

[80]  Jose M. Silva,et al.  Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer , 2001, Oncogene.

[81]  L. Norton,et al.  p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  F. Mitelman,et al.  Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients , 1998, Genes, chromosomes & cancer.

[83]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[84]  Patrick E Carroll,et al.  Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression , 1999, Oncogene.

[85]  J. D. Weber,et al.  The ARF/p53 pathway. , 2000, Current opinion in genetics & development.

[86]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[87]  S. Hirohashi,et al.  Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  A. Hanby,et al.  Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. , 1999, Cancer research.

[90]  B. Angus,et al.  Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study , 1992, The Journal of pathology.

[91]  L. Donehower Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. , 1996, Biochimica et biophysica acta.

[92]  N. Phillips,et al.  Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. , 1995, Cancer research.

[93]  A. Schäffer,et al.  Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. , 1997, Cancer research.

[94]  T. Rebbeck,et al.  Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. , 2001, American journal of clinical pathology.

[95]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[96]  S. Devries,et al.  Loss of chromosome 16q in lobular carcinoma in situ. , 2001, Human pathology.

[97]  M. Stratton,et al.  Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. , 1995, Journal of clinical pathology.

[98]  Hiroki Inui,et al.  Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy , 1993, Breast Cancer Research and Treatment.

[99]  S. Parsons,et al.  Src family kinases and HER2 interactions in human breast cancer cell growth and survival , 2001, Oncogene.

[100]  J. Coindre,et al.  The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases , 1995, Breast Cancer Research and Treatment.

[101]  D. Davey,et al.  Comparison of nuclear grade and DNA cytometry in breast carcinoma aspirates to histologic grade in excised cancers. , 1993, American journal of clinical pathology.

[102]  M. Melamed,et al.  Flow cytometry of breast carcinoma: I. Relation of DNA ploidy level to histology and estrogen receptor , 1981, Cancer.

[103]  C. Yue,et al.  Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene , 2001, Oncogene.

[104]  E. Gabrielson,et al.  Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. , 1996, Cancer research.

[105]  I. Andrulis,et al.  p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. , 1998, Cancer research.

[106]  J. Isola,et al.  Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. , 2001, Cancer research.

[107]  L. Holmberg,et al.  Ductal Carcinoma in Situ of the Breast: a New Phenotype Classification System and its Relation to Prognosis , 2002, Breast Cancer Research and Treatment.

[108]  A. Levine,et al.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[109]  F. Alt,et al.  Unrepaired DNA Breaks in p53-Deficient Cells Lead to Oncogenic Gene Amplification Subsequent to Translocations , 2002, Cell.

[110]  A. Zetterberg,et al.  Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. , 1994, Human pathology.

[111]  J. Schneider,et al.  Histological Grade in Breast Cancer: Association with Clinical and Biological Features in a Series of 229 Patients , 2001, The International journal of biological markers.

[112]  Ook Joon Yoo,et al.  Methylation in the p53 Promoter Is a Supplementary Route to Breast Carcinogenesis: Correlation between CpG Methylation in the p53 Promoter and the Mutation of the p53 Gene in the Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma , 2001, Laboratory Investigation.

[113]  R. Ridolfi,et al.  HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach , 2000, Modern Pathology.

[114]  A. Marchetti,et al.  Cyclin‐d1‐gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21waf1 immunohistochemical expression , 1997, International journal of cancer.

[115]  K. Lee,et al.  Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast , 2001, The Journal of pathology.

[116]  A. Lazaris,et al.  PROGNOSTIC SIGNIFICANCE OF THE CO‐EXPRESSION OF p53 AND c‐erbB‐2 PROTEINS IN BREAST CANCER , 1996, The Journal of pathology.

[117]  F. Speleman,et al.  Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer , 1997, Virchows Archiv.

[118]  M. Gnant,et al.  p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. , 1997, European journal of cancer.

[119]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[120]  M. Oren,et al.  Regulation of p53: intricate loops and delicate balances. , 2002, Biochemical pharmacology.

[121]  B. Lloveras,et al.  Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[122]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[123]  J. Schlom,et al.  Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. , 1986, Cancer research.

[124]  Tianhua Niu,et al.  Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c‐Jun towards cyclin D1 , 2001, The EMBO journal.

[125]  A. Marchetti,et al.  p53 Mutations and Histologie Type of Invasive Breast Carcinoma , 1993, Cancer research.

[126]  S. Naber,et al.  Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. , 2000, Cancer research.

[127]  M. Stenmark-Askmalm,et al.  Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. , 1994, European journal of cancer.

[128]  S Toikkanen,et al.  Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  R. Simon,et al.  Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast , 2000, Molecular pathology : MP.

[130]  A. Vincent-Salomon,et al.  Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns , 1996, Cancer.

[131]  G. Tamura,et al.  Epithelial‐cadherin Gene Is Not Mutated in Ductal Carcinomas of the Breast , 1995, Japanese journal of cancer research : Gann.

[132]  E. Frenkel,et al.  Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status , 2002, Modern Pathology.

[133]  O. Kallioniemi,et al.  Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and dna flow cytometry , 1990, Cancer.

[134]  L. Bonetta,et al.  Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. , 1994, Oncogene.

[135]  N. Hellyer,et al.  Heregulin-dependent Activation of Phosphoinositide 3-Kinase and Akt via the ErbB2/ErbB3 Co-receptor* , 2001, The Journal of Biological Chemistry.

[136]  M. Pagano,et al.  Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression. , 1994, Oncogene.

[137]  P. Steeg,et al.  Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity , 2004, Breast Cancer Research and Treatment.

[138]  W. Lee,et al.  Inactivation of the retinoblastoma susceptibility gene in human breast cancers. , 1988, Science.

[139]  P. Steeg,et al.  Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. , 1996, The American journal of pathology.

[140]  D K Gaffney,et al.  Pathobiologic characteristics of hereditary breast cancer. , 1998, Human pathology.

[141]  S. Devries,et al.  Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[142]  D. Horsfall,et al.  Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[143]  L. Neckers,et al.  Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. , 2001, Cancer research.

[144]  I. Macdonald,et al.  Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. , 2002, Cancer research.

[145]  D. Birnbaum,et al.  p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. , 1994, British Journal of Cancer.

[146]  C. Benz,et al.  Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. , 1989, Cancer research.

[147]  I. Ellis,et al.  Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. , 1995, British Journal of Cancer.

[148]  N. Phillips,et al.  Allelic loss and the progression of breast cancer. , 1995, Cancer research.

[149]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[150]  R. Millikan,et al.  p53 mutations in benign breast tissue. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  C. Redmond,et al.  DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S‐Phase fraction to outcome of patients in NSABP B‐04 , 1991, Cancer.

[152]  D. Barnes,et al.  Tumour grade does not change between primary and recurrent mammary carcinoma. , 1998, European journal of cancer.

[153]  U. Lehmann,et al.  Amplification of Growth Regulatory Genes in Intraductal Breast Cancer Is Associated with Higher Nuclear Grade but Not with the Progression to Invasiveness , 2001, Laboratory Investigation.

[154]  D. Visscher,et al.  Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast. , 1990, Archives of pathology & laboratory medicine.

[155]  G. Cserni,et al.  Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma. , 2002, Journal of Clinical Pathology.

[156]  S. Hirohashi,et al.  c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. , 1995, Biochemical and biophysical research communications.

[157]  J. Marks,et al.  Overexpression of p53 and HER‐2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer , 1994, Annals of surgery.

[158]  J. Peterse,et al.  Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type , 1999, British Journal of Cancer.

[159]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[160]  A. Leong,et al.  Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. , 2001, American journal of clinical pathology.

[161]  F. King,et al.  Hsp70 interactions with the p53 tumour suppressor protein , 2001, The EMBO journal.

[162]  W. J. Brammar,et al.  The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. , 1989, Oncogene.

[163]  J. Peterse,et al.  A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. , 1996, British Journal of Cancer.

[164]  L. Gu,et al.  Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[165]  S. Tsutsui,et al.  EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[166]  S. Lakhani The transition from hyperplasia to invasive carcinoma of the breast , 1999, The Journal of pathology.

[167]  M. J. van de Vijver,et al.  Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast , 1999, The Journal of pathology.

[168]  U. Lehmann,et al.  Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. , 2002, Cancer research.

[169]  G. Landberg,et al.  The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node , 2002, Oncogene.

[170]  A. Patchefsky,et al.  CCND1‐ and ERBB2‐gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast , 2002, Molecular carcinogenesis.

[171]  P. Dalla Palma,et al.  Cytometric DNA Analysis and Prognostic Biomarkers in Breast Carcinoma. Expression of P53 Product in the Different Ploidy Classes , 1997, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[172]  R. Sutherland,et al.  Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[173]  P. Sismondi,et al.  c‐erbB‐2 and ras expression levels in breast cancer are correlated and show a co‐operative association with unfavorable clinical outcome , 1991, International journal of cancer.

[174]  D. Germain,et al.  Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer , 1999, Oncogene.

[175]  P. V. van Diest,et al.  Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. , 1997, The American journal of pathology.

[176]  I. Ellis,et al.  p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. , 1992, British Journal of Cancer.

[177]  S. Kamel,et al.  Identification of a chemoprevention cohort from a population of women at high risk for breast cancer , 1996, Journal of cellular biochemistry. Supplement.

[178]  T. Shankey,et al.  Common patterns of genetic evolution in human solid tumors. , 1997, Cytometry.

[179]  W. El-Deiry p21/p53, cellular growth control and genomic integrity. , 1998, Current topics in microbiology and immunology.

[180]  C. Shimizu,et al.  c‐erbB‐2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues , 2000, Journal of surgical oncology.

[181]  A. Cleton-Jansen E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? , 2001, Breast Cancer Research.

[182]  C. Poremba,et al.  Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways , 1999, The Journal of pathology.

[183]  G R Stark,et al.  Regulation and mechanisms of mammalian gene amplification. , 1993, Advances in cancer research.

[184]  N. Rosen,et al.  Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. , 2002, Cancer research.

[185]  K. Vousden,et al.  Regulation and function of the p53 tumor suppressor protein. , 2001, Current opinion in cell biology.

[186]  P. Guldberg,et al.  Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients , 2000, Breast Cancer Research.

[187]  G. Inghirami,et al.  Tubular Carcinoma of the Breast: Immunohistochemical and DNA Flow Cytometric Profile , 1999, The breast journal.

[188]  M L Agarwal,et al.  The p53 Network* , 1998, The Journal of Biological Chemistry.

[189]  P. V. van Diest,et al.  Correlation of morphologic and cytogenetic parameters of genetic instability with chromosomal alterations in in situ carcinomas of the breast. , 2000, American journal of clinical pathology.

[190]  W. Lewis,et al.  Prognostic significance of flow cytometric DNA analysis in node‐negative breast cancer patients , 1990, Cancer.

[191]  P. V. van Diest,et al.  Genetic analysis of 53 lymph node‐negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors , 1998, The Journal of pathology.

[192]  J. Bartek,et al.  Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. , 1993, European journal of cancer.

[193]  S. Hirohashi,et al.  Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer. , 1997, Japanese journal of clinical oncology.

[194]  M. Aapro,et al.  Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. , 1989, Cancer research.

[195]  P. Devilee,et al.  Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss , 1992, International journal of cancer.

[196]  H. Sasano,et al.  Immunolocalization of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human breast carcinoma. , 1997, Anticancer research.

[197]  B. Iacopetta,et al.  Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[198]  R. Soslow,et al.  A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas , 2000, Breast Cancer Research and Treatment.

[199]  Kristen L Murphy,et al.  Mutant p53 and genomic instability in a transgenic mouse model of breast cancer , 2000, Oncogene.

[200]  J. Bartek,et al.  Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity , 1995, Molecular and cellular biology.

[201]  B. Dutrillaux,et al.  Breast cancer genetic evolution: I. Data from cytogenetics and DNA content , 1991, Breast Cancer Research and Treatment.

[202]  I. Ellis,et al.  Prognostic significance of the DNA content of human breast cancer , 1987, The British journal of surgery.

[203]  M. J. van de Vijver,et al.  Simultaneous loss of E‐cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ , 1997, The Journal of pathology.

[204]  F. O'Malley,et al.  Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. , 1997, The American journal of pathology.

[205]  Y. Yarden,et al.  Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.

[206]  T. Crook,et al.  The p53 pathway in breast cancer , 2002, Breast Cancer Research.

[207]  O. Gröntoft,et al.  Cytometric and histopathologic features of tumors detected in a randomized mammography screening program: Correlation and relative prognostic influence , 1990, Breast Cancer Research and Treatment.

[208]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[209]  S. Hirohashi,et al.  correlation between histologic grade of malignancy and copy number of c‐erbb‐2 gene in breast carcinoma. A retrospective analysis of 176 cases , 1990, Cancer.

[210]  J. Eyfjörd,et al.  p53 abnormalities and genomic instability in primary human breast carcinomas. , 1995, Cancer research.

[211]  K. Weber,et al.  Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. , 1993, The American journal of pathology.

[212]  C. Howe,et al.  Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. , 2001, Experimental and molecular pathology.

[213]  P. Bontempo,et al.  Estradiol induces functional inactivation of p53 by intracellular redistribution. , 2000, Cancer research.

[214]  J. Biggart,et al.  c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. , 1992, Journal of clinical pathology.

[215]  L. Holmberg,et al.  Tumour markers in breast carcinoma correlate with grade rather than with invasiveness , 2001, British Journal of Cancer.

[216]  M. Merino,et al.  Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions , 1995, Nature Medicine.

[217]  M. Kraus,et al.  Increased erbB-2 gene copies and expression in multiple stages of breast cancer. , 1990, Cancer research.

[218]  S. Lowe,et al.  Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[219]  F. Koerner,et al.  Lobular Carcinoma in Situ and Infiltrating Ductal Carcinoma: Frequent Presence of DCIS as a Precursor Lesion , 2001, International journal of surgical pathology.

[220]  T. Rohan,et al.  Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[221]  E. Schröck,et al.  Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation , 1999, Genes, chromosomes & cancer.

[222]  V. Kosma,et al.  Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. , 1995, European journal of cancer.

[223]  J. Marks,et al.  Maintenance of p53 alterations throughout breast cancer progression. , 1991, Cancer research.

[224]  J. Foekens,et al.  Association between rb‐1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival , 1995, International journal of cancer.

[225]  Bart,et al.  Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit , 1996, Molecular and cellular biology.

[226]  J. Herman,et al.  Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise. , 2000, Journal of the National Cancer Institute.

[227]  G. Landberg,et al.  Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein , 1997, Oncogene.

[228]  Yong-jie Lu,et al.  Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. , 1998, Cancer research.

[229]  S. Shackney,et al.  Karyotypic evolution of a human undifferentiated large cell carcinoma of the lung in tissue culture. , 1989, Cancer research.

[230]  D. Horsfall,et al.  Relationship between p53 gene abnormalities and other tumour characteristics in breast‐cancer prognosis , 1996, International journal of cancer.

[231]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[232]  M. Redston,et al.  p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. , 2001, Journal of the National Cancer Institute.

[233]  G. Hortobagyi,et al.  Her-2/neu gene amplification in ductal carcinoma in situ of the breast. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[234]  W. Dupont,et al.  p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[235]  G. Serio,et al.  p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. , 1992, American journal of clinical pathology.